Latest Financial Strategy News

Tryptamine Therapeutics has locked in $2.6 million in non-dilutive funding to fast-track clinical trials of its lead psilocin-based therapy, TRP-8803, targeting binge eating disorder and other conditions.

Clime Capital Limited reports an unaudited $3 million profit for FY25, plans a September dividend, and kicks off FY26 with a profitable July.

Platinum Capital Limited has pulled its proposed scheme of arrangement due to insufficient shareholder support but will proceed with an on-market buy-back. Meanwhile, L1 Capital pushes for management control and board renewal.

InteliCare Holdings reported a $564,000 operating cash outflow in Q4 2025 and has secured $1 million in additional funding to support ongoing operations despite a cash runway under one quarter.

Cluey Ltd has reported its first-ever positive quarterly operating cash flow, marking a key financial milestone and signaling a strategic shift towards AI-led innovation and sustainable growth.

Citigold Corporation Limited reports steady progress in exploration and mine design at its Charters Towers Gold Project, while actively pursuing funding partnerships to restart operations.

BWP Property Group and BWP Trust have launched a new Distribution Reinvestment Plan allowing stapled securityholders to reinvest cash distributions into additional securities, potentially at a discount and without transaction costs.

Chimeric Therapeutics has advanced its CHM CDH17 CAR-T program with dose escalation and FDA Fast Track status, alongside promising early results in AML trials and a successful $6.6 million capital raise.

Garda Property Group has entered a call option agreement with Halpin Property Group to sell its Cairns Corporate Tower for $77.5 million, slightly above valuation, aiming to reduce debt and sharpen its asset focus.

Cuscal Limited announces the retirement of long-serving CFO Sean O’Donoghue in late 2025 and the appointment of Jennifer Brice as his successor, signaling a seamless leadership transition as the company remains on track to meet its FY25 forecasts.

Zelira Therapeutics has locked in a $650,000 loan facility secured against its anticipated FY25 R&D tax rebate, aiming to accelerate its HOPE SPV clinical trial and strengthen working capital.

Tshipi é Ntle has declared a ZAR300 million final dividend for FY2025 H2, with Jupiter Mines set to receive approximately A$12.3 million. This payout underscores the manganese mine’s robust cash flow generation amid market cycles.